Persistent Activation of Sphingosine-1-Phosphate Receptor 1 by Phytosphingosine-3,4-Cyclic Phosphate Ameliorates Sepsis by Inhibiting Hyperinflammation and Vascular Hyperpermeability

Abstract

Sepsis is a life-threatening disease characterized by multiorgan dysfunction caused by an abnormal immune response to microbial infection. Sphingosine-1-phosphate (S1P) levels are significantly lower in patients with sepsis and are negatively correlated with the severity of sepsis. However, whether the S1P signaling pathway is a target for sepsis treatment remains unknown. Here, we show that our newly synthesized phytosphingosine-3,4-cyclic phosphate (3,4-cPP), a functional agonist of S1P receptor 1 (S1P1), exerts a strong protective effect against severe cecal ligation and puncture (CLP)-induced sepsis. 3,4-cPP persistently activates S1P1 without inducing internalization. 3,4-cPP upregulates SIRT1 expression in macrophages and endothelial cells via S1P1 activation. Additionally, 3,4-cPP decreases serum levels of proinflammatory cytokines, including IL-6 and TNF-α, and inhibits endothelial permeability in CLP-induced septic mice. Conditional knockout of SIRT1, an NAD⁺-dependent deacetylase, in macrophages or endothelial cells counteracts the inhibition of inflammatory cytokine secretion and prevention of endothelial cell permeability by 3,4-cPP in CLP-induced septic mice, indicating that the S1P1/SIRT1 axis in both the endothelium and macrophages is essential for survival in sepsis. Collectively, the data suggest that prolonged activation of the S1P1/SIRT1 signaling pathway protects against sepsis by inhibiting hyperinflammation and vascular hyperpermeability.

Keywords

cecal ligation and puncture / phytosphingosine-3,4-cyclic phosphate / sepsis / sirtuin 1 (SIRT1) / sphingosine-1-phosphate / sphingosine-1-phosphate receptor 1

References

[1] M. Singer, C. S. Deutschman, C. W. Seymour, et al., “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),” Jama 315, no. 8 (2016): 801-810.

[2] A. Rhodes, L. E. Evans, W. Alhazzani, et al., “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” Intensive Care Medicine 43, no. 3 (2017): 304-377.

[3] C. Nedeva, J. Menassa, and H. Puthalakath, “Sepsis: Inflammation Is a Necessary Evil,” Frontiers in Cell and Developmental Biology 7 (2019): 108.

[4] A. Spicer and C. S. Calfee, “Fixing the Leak: Targeting the Vascular Endothelium in Sepsis,” Critical Care (London, England) 16, no. 6 (2012): 177.

[5] W. L. Lee and A. S. Slutsky, “Sepsis and Endothelial Permeability,” New England Journal of Medicine 363, no. 7 (2010): 689-691.

[6] W. C. Aird, “The Role of the Endothelium in Severe Sepsis and Multiple Organ Dysfunction Syndrome,” Blood 101, no. 10 (2003): 3765-3777.

[7] S. Weinbaum, J. M. Tarbell, and E. R. Damiano, “The Structure and Function of the Endothelial Glycocalyx Layer,” Annual Review of Biomedical Engineering 9 (2007): 121-167.

[8] C. Ince, P. R. Mayeux, T. Nguyen, et al., “The Endothelium in Sepsis,” Shock (Augusta, Ga.) 45, no. 3 (2016): 259-270.

[9] C. S. Alphonsus and R. N. Rodseth, “The Endothelial Glycocalyx: A Review of the Vascular Barrier,” Anaesthesia 69, no. 7 (2014): 777-784.

[10] D. Pretorius, R. P. Richter, T. Anand, J. C. Cardenas, and J. R. Richter, “Alterations in Heparan Sulfate Proteoglycan Synthesis and Sulfation and the Impact on Vascular Endothelial Function,” Matrix Biol Plus 16 (2022): 100121.

[11] E. P. Schmidt, Y. Yang, W. J. Janssen, et al., “The Pulmonary Endothelial Glycocalyx Regulates Neutrophil Adhesion and Lung Injury During Experimental Sepsis,” Nature Medicine 18, no. 8 (2012): 1217-1223.

[12] R. Uchimido, E. P. Schmidt, and N. I. Shapiro, “The Glycocalyx: A Novel Diagnostic and Therapeutic Target in Sepsis,” Critical Care (London, England) 23, no. 1 (2019): 16.

[13] M. I. Lygizos, Y. Yang, C. J. Altmann, et al., “Heparanase Mediates Renal Dysfunction During Early Sepsis in Mice,” Physiological Reports 1, no. 6 (2013): e00153.

[14] B. F. Becker, M. Jacob, S. Leipert, A. H. Salmon, and D. Chappell, “Degradation of the Endothelial Glycocalyx in Clinical Settings: Searching for the Sheddases,” British Journal of Clinical Pharmacology 80, no. 3 (2015): 389-402.

[15] A. Cartier and T. Hla, “Sphingosine 1-phosphate: Lipid Signaling in Pathology and Therapy,” Science 366, no. 6463 (2019).

[16] K. Avery, S. Avery, J. Shepherd, P. R. Heath, and H. Moore, “Sphingosine-1-phosphate Mediates Transcriptional Regulation of Key Targets Associated With Survival, Proliferation, and Pluripotency in human Embryonic Stem Cells,” Stem Cells and Development 17, no. 6 (2008): 1195-1205.

[17] Y. Zeng, R. H. Adamson, F. R. Curry, and J. M. Tarbell, “Sphingosine-1-phosphate Protects Endothelial Glycocalyx by Inhibiting Syndecan-1 Shedding,” American Journal of Physiology. Heart and Circulatory Physiology 306, no. 3 (2014): H363-372.

[18] Y. Zeng, X. H. Liu, J. Tarbell, and B. Fu, “Sphingosine 1-phosphate Induced Synthesis of Glycocalyx on Endothelial Cells,” Experimental Cell Research 339, no. 1 (2015): 90-95.

[19] H. M. Al-Kuraishy, G. E. Batiha, A. I. Al-Gareeb, N. A. H. Al-Harcan, and N. N. Welson, “Receptor-dependent Effects of Sphingosine-1-phosphate (S1P) in COVID-19: The Black Side of the Moon,” Molecular and Cellular Biochemistry 478, no. 10 (2023): 2271-2279.

[20] A. C. Ziegler and M. H. Graler, “Barrier Maintenance by S1P During Inflammation and Sepsis,” Tissue Barriers 9, no. 4 (2021): 1940069.

[21] M. S. Winkler, A. Nierhaus, M. Holzmann, et al., “Decreased Serum Concentrations of Sphingosine-1-phosphate in Sepsis,” Critical Care (London, England) 19 (2015): 372.

[22] M. Ksiazek, M. Chacinska, A. Chabowski, and M. Baranowski, “Sources, Metabolism, and Regulation of Circulating Sphingosine-1-phosphate,” Journal of Lipid Research 56, no. 7 (2015): 1271-1281.

[23] K. Venkataraman, Y. M. Lee, J. Michaud, et al., “Vascular Endothelium as a Contributor of Plasma Sphingosine 1-phosphate,” Circulation Research 102, no. 6 (2008): 669-676.

[24] V. Brinkmann, A. Billich, T. Baumruker, et al., “Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis,” Nature Reviews Drug Discovery 9, no. 11 (2010): 883-897.

[25] Y. Ikeda, M. I. Davis, K. Sumita, et al., “Multimodal Action of KRP203 on Phosphoinositide Kinases in Vitro and in Cells,” Biochemical and Biophysical Research Communications 679 (2023): 116-121.

[26] M. H. Bolli, S. Abele, C. Binkert, et al., “2-imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1 Receptor Agonists,” Journal of Medicinal Chemistry 53, no. 10 (2010): 4198-4211.

[27] S. Teymouri, S. Pourbayram Kaleybar, S. S. Hejazian, et al., “The Effect of Fingolimod on Patients With Moderate to Severe COVID-19,” Pharmacol Res Perspect 11, no. 1 (2023): e01039.

[28] G. Dell'Omo, D. Crescenti, C. Vantaggiato, et al., “Inhibition of SIRT1 Deacetylase and p53 Activation Uncouples the Anti-inflammatory and Chemopreventive Actions of NSAIDs,” British Journal of Cancer 120, no. 5 (2019): 537-546.

[29] R. Gao, Z. Ma, Y. Hu, J. Chen, S. Shetty, and J. Fu, “Sirt1 restrains Lung Inflammasome Activation in a Murine Model of Sepsis,” American Journal of Physiology. Lung Cellular and Molecular Physiology 308, no. 8 (2015): L847-853.

[30] C. H. Yoo, J. H. Yeom, J. J. Heo, E. K. Song, S. I. Lee, and M. K. Han, “Interferon Beta Protects Against Lethal Endotoxic and Septic Shock Through SIRT1 Upregulation,” Scientific Reports 4 (2014): 4220.

[31] S. Duan, S. G. Kim, H. J. Lim, H. R. Song, and M. K. Han, “Interferon-beta Alleviates Sepsis by SIRT1-mediated Blockage of Endothelial Glycocalyx Shedding,” BMB Rep 56, no. 5 (2023): 314-319.

[32] Z. Gao, H. Wang, F. J. Xiao, et al., “SIRT1 mediates Sphk1/S1P-induced Proliferation and Migration of Endothelial Cells,” International Journal of Biochemistry & Cell Biology 74 (2016): 152-160.

[33] K. Chiba, “FTY720, a New Class of Immunomodulator, Inhibits Lymphocyte Egress From Secondary Lymphoid Tissues and thymus by Agonistic Activity at Sphingosine 1-phosphate Receptors,” Pharmacology & Therapeutics 108, no. 3 (2005): 308-319.

[34] K. Chiba, H. Matsuyuki, Y. Maeda, and K. Sugahara, “Role of Sphingosine 1-phosphate Receptor Type 1 in Lymphocyte Egress From Secondary Lymphoid Tissues and thymus,” Cell Mol Immunol 3, no. 1 (2006): 11-19.

[35] Y. S. Hah, Y. H. Cheon, H. S. Lim, et al., “Myeloid Deletion of SIRT1 Aggravates Serum Transfer Arthritis in Mice via Nuclear Factor-kappaB Activation,” PLoS ONE 9, no. 2 (2014): e87733.

[36] W. Zhang, Y. Zhang, X. Guo, et al., “Sirt1 Protects Endothelial Cells Against LPS-Induced Barrier Dysfunction,” Oxid Med Cell Longev 2017 (2017): 4082102.

[37] J. X. Liu, Z. P. Yan, Y. Y. Zhang, J. Wu, X. H. Liu, and Y. Zeng, “Hemodynamic Shear Stress Regulates the Transcriptional Expression of Heparan Sulfate Proteoglycans in human Umbilical Vein Endothelial Cell,” Cellular and Molecular Biology 62, no. 8 (2016): 28-34.

[38] Y. Zeng and J. M. Tarbell, “The Adaptive Remodeling of Endothelial Glycocalyx in Response to Fluid Shear Stress,” PLoS ONE 9, no. 1 (2014): e86249.

[39] F. Xiao, D. Wang, L. Kong, et al., “Intermedin Protects Against Sepsis by Concurrently Re-establishing the Endothelial Barrier and Alleviating Inflammatory Responses,” Nature Communications 9, no. 1 (2018): 2644.

[40] Q. Xu, J. Guo, X. Li, et al., “Necroptosis Underlies Hepatic Damage in a Piglet Model of Lipopolysaccharide-Induced Sepsis,” Frontiers in immunology 12 (2021): 633830.

[41] J. Jalkanen, S. Khan, K. Elima, et al., “Polymorphism in Interferon Alpha/Beta Receptor Contributes to Glucocorticoid Response and Outcome of ARDS and COVID-19,” Critical Care (London, England) 27, no. 1 (2023): 112.

[42] M. Karam and C. Auclair, “Sphingosine-1-Phosphate as Lung and Cardiac Vasculature Protecting Agent in SARS-CoV-2 Infection,” International Journal of Molecular Sciences 24, no. 17 (2023).

[43] C. Lelubre and J. L. Vincent, “Mechanisms and Treatment of Organ Failure in Sepsis,” Nature Reviews Nephrology 14, no. 7 (2018): 417-427.

[44] S. M. Coldewey, E. Benetti, M. Collino, et al., “Elevation of Serum Sphingosine-1-phosphate Attenuates Impaired Cardiac Function in Experimental Sepsis,” Scientific Reports 6 (2016): 27594.

[45] G. Marfia, S. Navone, L. Guarnaccia, et al., “Decreased Serum Level of Sphingosine-1-phosphate: A Novel Predictor of Clinical Severity in COVID-19,” EMBO Molecular Medicine 13, no. 1 (2021): e13424.

[46] V. Natarajan, S. M. Dudek, J. R. Jacobson, et al., “Sphingosine-1-phosphate, FTY720, and Sphingosine-1-phosphate Receptors in the Pathobiology of Acute Lung Injury,” American Journal of Respiratory Cell and Molecular Biology 49, no. 1 (2013): 6-17.

[47] C. Uzunkopru, Y. Beckmann, and S. Ture, “Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting,” European Neurology 84, no. 3 (2021): 200-205.

[48] J. Chun and H. P. Hartung, “Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis,” Clinical Neuropharmacology 33, no. 2 (2010): 91-101.

[49] J. Jin, N. Xue, Y. Liu, et al., “A Novel S1P1 Modulator IMMH002 Ameliorates Psoriasis in Multiple Animal Models,” Acta Pharm Sin B 10, no. 2 (2020): 276-288.

[50] L. G. Noriega, J. N. Feige, C. Canto, et al., “CREB and ChREBP Oppositely Regulate SIRT1 Expression in Response to Energy Availability,” Embo Reports 12, no. 10 (2011): 1069-1076.

[51] S. Xiong, G. Salazar, N. Patrushev, and R. W. Alexander, “FoxO1 mediates an Autofeedback Loop Regulating SIRT1 Expression,” Journal of Biological Chemistry 286, no. 7 (2011): 5289-5299.

[52] S. Nemoto, M. M. Fergusson, and T. Finkel, “Nutrient Availability Regulates SIRT1 Through a Forkhead-dependent Pathway,” Science 306, no. 5704 (2004): 2105-2108.

[53] S. H. Lee, J. H. Yang, U. H. Park, et al., “SIRT1 ubiquitination Is Regulated by Opposing Activities of APC/C-Cdh1 and AROS During Stress-induced Premature Senescence,” Experimental & Molecular Medicine 55, no. 6 (2023): 1232-1246.

[54] F. Poti, M. Simoni, and J. R. Nofer, “Atheroprotective Role of High-density Lipoprotein (HDL)-associated Sphingosine-1-phosphate (S1P),” Cardiovascular Research 103, no. 3 (2014): 395-404.

[55] F. Shah, A. F. Stepan, A. O'Mahony, et al., “Mechanisms of Skin Toxicity Associated With Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators,” Cell Chem Biol 24, no. 7 (2017): 858-869. e5.

[56] J. Jiang, K. Huang, S. Xu, J. G. N. Garcia, C. Wang, and H. Cai, “Targeting NOX4 Alleviates Sepsis-induced Acute Lung Injury via Attenuation of Redox-sensitive Activation of CaMKII/ERK1/2/MLCK and Endothelial Cell Barrier Dysfunction,” Redox Biology 36 (2020): 101638.

[57] Z. Liu, N. Li, H. Fang, et al., “Enteric Dysbiosis Is Associated With Sepsis in Patients,” Faseb Journal 33, no. 11 (2019): 12299-12310.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.